Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.22.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Revenue $ 15,374 $ 12,117
Cost of sales:    
Cost of sales, before inventory write-down (5,585) (4,305)
Inventory write-down (2,980) (399)
Total cost of sales (8,565) (4,704)
Gross profit 6,809 7,413
Expenses    
General and administrative 38,398 28,819
Sales and marketing 3,796 2,577
Research and development 1,546 1,009 [1]
Goodwill impairment 18,508 1,682
Depreciation and amortization 1,768 1,854
Total expenses 64,016 35,941
Loss from operations (57,207) (28,528)
Other Expense (Income), net    
Interest and amortization of debt issuance cost 6,818 4,455
Gain on remeasurement of warrant liability (16,856) (10,780)
Loss on investments 0 464
(Gain) loss on debt extinguishment, net (3,262) 2,360
Loss on fair value of derivative instrument 0 657
Foreign exchange loss 1,276 491
Other income, net (502) (284)
Total other income, net (12,526) (2,637)
Loss before income taxes and equity investment loss (44,681) (25,891)
Deferred income tax expense 950 0
Equity investment share of loss 95 4
Net loss $ (45,726) $ (25,895)
Net loss per share - basic (dollars per share) $ (1.78) $ (3.34)
Net loss per share - diluted (dollars per share) $ (1.78) $ (3.34)
Weighted-average common shares outstanding - basic (in shares) 25,690,096 10,815,580
Weighted-average common shares outstanding - diluted (in shares) 25,690,096 10,815,580
[1] The Company reclassified $1,009 research and development expenses, reported in previous period in general and development expense, to conform to the current period presentation.